Background: ThehighvariabilityinclinicalmanifestationsofFabrydiseasecanleadto
| INTRODUCTION
Until recently, Fabry disease in women was thought to be largely asymptomatic, 1 but closer observations have revealed that women may experience the same signs and symptoms as men, although typically with a higher degree of variability and occurring laterinlife. 5, 6 Enzyme replacement therapy (ERT) has been shown to stabilise and improve many of the signs and symptoms of Fabry disease.
7-12
Startingtreatmentearlyinthediseasecoursemayhalttheprogression towardsirreversibleorgandamageandthesubsequentdevelopment ofassociatedlife-threateningcomplications.Unfortunately,thediagnosis of Fabry disease is confounded by high variability in terms of organsysteminvolvement,ageatonset,andseverityofFabrydisease clinicalfeatures,oftenresultinginmisdiagnosisordelayeddiagnosis. 13 Patientsmayseekhelpfrommultiplemedicalspecialistsbeforeacorrectdiagnosisismade,resultingindelayedtreatmentinitiation.
AstudyofdatafromtheFabryOutcomeSurvey(FOS),soonafter
ERTforFabrydiseasebecameavailablein2001,identifiedmeandelays fromsymptomonsettocorrectFabrydiseasediagnosisof13.7years inmalesand16.3yearsinfemales. 
| MATERIALS AND METHODS

| Patients and study design
| Data analysis
| Statistical analyses
Descriptivestatisticswerecalculatedanddifferenceswereassessed usingFisher'sexacttestsforcategoricalvariablesandWilcoxonranksum tests for continuous variables. The analyses were performed usingSASversion9.2(SASInstituteInc.,Cary,NC,USA). 
| RESULTS
| Delay in diagnosis
A trend towards early diagnosis was noted for both children and adults,althoughnoneofthedifferenceswerestatisticallysignificant (Table1).Moreover,manypatientscontinuetoexperiencedelaysin increaseinthenumberofcentresparticipatinginFOSandthesubsequent increase in the number of patents registered in the latter period.
| Delay in treatment onset
| Geographical analysis
| Disease expression and diagnosis by medical specialists
| DISCUSSION
| Delay in diagnosis
Thisstudyshowsthat,overall,thedelayinFabrydiseasediagnosishas shownanon-significanttrendtowardsimprovementinrecentyears.
It also shows that ERT now seems to be initiated sooner after diagnosis than when it first became available. We found a similar mean delayinFabrydiseasediagnosisinadultsinrecentyearstothatofthe 13.7yearsformalesand16.3yearsforfemalesdescribedbyMehta
etal. 6 and also the 12.2years for males and 12.4years for females reported by Beck.
14 Moreover, the Fabry Registry reported an even larger gap between median age at symptom onset and diagnosis of 14 years for males and 19years for females. 15 In agreement with findings from Mehta etal., ;therefore,the"cumulativeimpact"ofpromptdiagnosiswithinafamilyisnotnegligible. although the definitions used to identify these Fabry disease variantswerenotprovided. 
| Delay in treatment onset
| Disease expression and diagnosis by medical specialists
| CONCLUSIONS
Our analysis shows that the delay in diagnosis has decreased, but notsignificantly,whilethedelayintreatmentonsethasshownastatistically significant improvement. Geographical differences have an impact on both parameters, and the causes of regional differences should be investigated further to gather evidence on this neglected (3) 8 (2) 12 (5) 39 (23) 38 (8) 74 (31) 1 (4) 8 (5) 9 (9) 25 (20) 32 (13) 57 ( 2007-2013 n(missing) 1 (7) 8 (5) 9 (12) 30 (30) 35 (29) 65 (59) 2 (4) 12 (7) 14 (11) 52 (37) 77 (32) 129 ( 
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